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Novelty statement (bulleted, up to 100 words) 
 This is the first study to evaluate use of capillary blood samples, collected 
at home by families themselves, for islet autoantibody testing. 
 Capillary sampling was feasible and acceptable in all age groups 
including young children, with high rates of success in testing for GAD, 
IA2 and ZnT8 autoantibodies. 
 The study highlights that insulin autoantibody assays were least likely to 
be successful, and therefore to avoid missing very young children at risk, 
second line venous sampling may be required in this group.  
 Screening of islet autoantibodies using this method is popular with 
families of people with type 1 diabetes, particularly children. 
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Abstract 
Aims: To evaluate the feasibility of using self-collected capillary blood samples 
for islet autoantibody testing to identify risk in relatives of people with type 1 
diabetes.  
Methods: Participants were recruited via the observational TrialNet Pathway to 
Prevention study, which screens and monitors relatives of people with type 1 
diabetes for islet autoantibodies.  Relatives were sent kits for capillary blood 
collection, with written instructions, an online instructional video link and a 
questionnaire. Sera from capillary blood samples were tested for autoantibodies 
to glutamic acid decarboxylase (GADA), islet antigen-2 (IA-2A), insulin (IAA), 
and zinc transporter 8 (ZnT8A). ‘Successful’ collection was defined as obtaining 
sufficient volume and quality to provide definitive autoantibody results, including 
confirmation of positive results by repeat assay. 
Results:  In 240 relatives who returned samples, the median age was 15.5 
years (range 1-49) and 51% were male. Of these samples, 98% were 
sufficient for GADA/IA-2A/ZnT8A, and 84% for IAA testing and complete 
autoantibody screen. The upper 90% confidence bound for unsuccessful 
collection was 4.4% for GADA, IA-2A and/or ZnT8A assays, and 19.3% for IAA. 
Despite 43% of 220 questionnaire respondents finding capillary blood collection 
uncomfortable or painful, 82% preferred home self-collection of capillary blood 
samples compared with outpatient venepuncture (90% <8 years, 83% 9-8 years 
and 73% >18 years). The perceived difficulty of collecting capillary blood 
samples did not affect success rate. 
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Conclusions: Self-collected capillary blood sampling offers a feasible 
alternative to venous sampling, with the potential to facilitate autoantibody 
screening for type 1 diabetes risk. 
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Introduction 
Islet autoantibodies are indicators of β-cell autoimmunity and individuals with 
two or more islet autoantibodies have >80% risk of developing type 1 diabetes 
within 15 years[1]. A recent type 1 diabetes staging classification system 
emphasised the importance of identifying islet autoimmunity in early pre-
symptomatic stages, potentially allowing for earlier intervention[2]. Prevention of 
progression to symptomatic disease requires large-scale screening to identify 
individuals at risk. Barriers to screening include geographical, cost and time 
constraints, as well as aversion to venepuncture, particular in children. A simple 
test allowing self-collection of samples at home could overcome these 
limitations. Capillary sampling, having previously been validated against 
venous sampling for detection of islet autoantibodies[3–5], offers a potential 
solution. We assessed feasibility and acceptability of home self-collection of 
capillary samples for autoantibody screening in relatives of people with type 1 
diabetes.   
 
Methods 
The TrialNet Pathway to Prevention (PTP) study[6] recruited relatives from 15 
US centres between August and December 2015. Institutional review boards 
at each centre provided ethical approval. Families provided written 
informed consent. Some centres offered telephone consultations with 
postal return of consent forms. Samples were tested for GADA, IA-2A, IAA, 
and ZnT8A in accordance with the PTP study protocol replacing venous 
sampling. Participants positive for ≥1 autoantibody or with unsuccessful 
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capillary sampling were recalled for confirmatory venous testing. Age-banded 
recruitment ensured enrolment of adequate numbers of younger children.  
 
Capillary sampling kits, containing BD Microtainer® contact-activated lancets 
(Becton Dickinson, Franklin Lakes, NJ), Sarstedt Microvette® serum gel 
capillary tubes with clotting activator (Sarstedt Inc., Newton, NC) with written 
and online instructions were provided in person or by post. A minimum 
volume of 200µl (up to 500µl) was requested. Adults performed the procedure 
on children <12 years, whilst children aged 12-17 collected samples 
themselves, or aided by an adult. Acceptability of collection was assessed by 
questionnaire (supplementary materials). Samples were returned to clinical sites 
by overnight courier. Extracted serum was stored and sent to the central 
laboratory at -20oC. 
  
GADA, IA-2A, ZnT8A, and IAA in capillary serum samples were measured by 
radioimmunoassay in the TrialNet Core laboratory at the Barbara Davis Center 
for Childhood Diabetes as previously described [6]. The same autoantibody 
cut-offs were used for capillary serum as used for venous serum in TrialNet 
studies.  
 
The primary outcome of the study was successful sample collection, defined as 
sufficient volume and quality (e.g. without excessive haemolysis) to allow 
definitive autoantibody results, including confirmation of positive results by 
repeat assay. Secondary outcomes incorporated acceptability of sample 
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collection and additional analyses to formulate an upper confidence bound of 
unsuccessful sampling.  
 
Results are presented as median (range) unless otherwise stated. The upper 
confidence bound of unsuccessful sampling was calculated using the Clopper-
Pearson interval. Chi-squared tests were performed for categorical values. 
Non-parametric questionnaire scoring data were compared using Wilcoxon rank 
sum and Kruskal-Wallis testing. Logistic regression was used to test for age 
effects in the risk of unsuccessful sample collection.  P-values <0.05 were 
considered significant. Statistical analysis was performed using SAS (SAS, Inc.) 
and S-PLUS (TIBCO Software Inc.) software.    
 
Results 
Table 1 summarises the demographic characteristics of participants. The 
median interval between initial shipment and sample collection was 8 days (0-
104) (n=158) and from sample collection to receipt at clinical centre was 2 days 
(0-7) (n=169). 
 
Rates of successful sample collection varied by autoantibody type (Table 1) with 
highest success for GADA, IA-2A and ZnT8A screening. There was no 
significant haemolysis in any samples.  
 
Upper 90% confidence bounds of unsuccessful capillary sample collection 
were 4.4% for GADA, IA-2A and ZnT8A assays combined, and 19.3% for IAA. 
Sampling was unsuccessful for ≥1 autoantibody assay in 16.0% of those aged 
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≤8, 17.5% aged 9-18 and 14.5% aged >18 years. There was no difference in 
rate of unsuccessful sampling between age groups or overall age effect 
(p=0.73).  
 
Of five participants with positive autoantibodies, four had confirmatory 
venous testing. Three showed fully concordant venous and capillary 
results and one was concordant for GADA and IA-2A positivity but an IAA 
positive capillary sample was negative on venous sampling.  Of 39 
individuals with unsuccessful capillary sampling six have provided 
venous samples to date. All capillary samples were insufficient for IAA 
only and in subsequent venous samples one individual was IAA positive 
and 5 were IAA negative. 
 
Capillary collection was considered uncomfortable or painful by 43%. 
Nonetheless, 82% preferred home capillary sampling over outpatient 
venepuncture. Preference for capillary sampling varied by age; 90% ≤8 years, 
83% of 9-18 year-olds and 73% of >18 year-olds, with greater preference 
among younger children (p=0.01). Median score for ease of testing using a 
scale from 1 (easy) to 7 (difficult), was 3 (interquartile range: 2-5) with no 
differences between age groups: 3 (2-5) ≤8 years, 3 (1-4) in 9-18 year-olds and 
2 (2-5) >18 years (p=0.39), nor between respondents with successful, compared 
with unsuccessful, sample collection (p=0.10). 
 
Written instructions were reported as easily understandable by 83.2%. Only 
53.6% watched the instructional video, with rate of successful sampling being 
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76.9% in those who watched versus 85.9% in those who did not (p=0.09). There 
was no difference in reported difficulty of the procedure between those who 
watched the video, median score 3 (2-4) and those who did not, 2 (2-5) 
(p=0.10).  
 
Discussion 
Ease of sample collection has allowed widespread adoption of capillary 
sampling in commercial self-testing for conditions such as 
hypercholesterolaemia and coeliac disease. Collection by clinicians has been 
used successfully for large-scale islet autoantibody testing in children[9] 
including those as young as 2 years[10,11]. However no published data exist 
on self-collection of capillary samples for islet autoantibody testing outside the 
clinical setting.  
 
Capillary samples have shown high concordance with venous samples when 
compared for GADA[3–5], IA-2A[3–5] (or combined GADA/IA-2A assays)[3,4], 
ZnT8A[5] and IAA[4]. Using a panel of GADA, IA-2A and ZnT8A assays, we 
have previously shown that 95.5% of individuals who were multiple autoantibody 
positive in venous serum were concordant in capillary samples collected as 
dried blood spots and 98.6% of those who were autoantibody negative were 
concordant in dried blood spot samples[5]. 
 
Options for self-collection of capillary samples are direct collection of whole 
blood into tubes or dried blood spots on filter paper, with extraction of serum or 
eluates respectively. Both techniques offer sufficient stability to allow samples to 
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be shipped at ambient temperature. Antibody levels are lower in dried blood 
eluates than in venous serum, particularly IAA, and weakly positive 
autoantibodies may be missed[3] introducing a risk of overlooking individuals 
with a single positive autoantibody. Our previous study which did not include IAA 
in the initial screen, showed 39% of relatives who were single autoantibody 
positive in a venous sample were missed by dried blood spot sampling[5]. 
Assay optimisation on dried blood spots has improved detection of 
IAA[12], however collection of dried capillary samples, even by clinicians, 
resulted in variable quality with 45% of samples insufficient to allow 
confirmation of positive results[5].This limits adoption of dried blood spots 
in screening strategies, but collecting capillary whole blood into tubes could 
overcome these issues.  
Of self-collected capillary samples, 16% were suboptimal for testing for all 
four autoantibodies, due to insufficient volumes for IAA measurement, whereas 
only 3% were insufficient to measure GADA, IA-2A and ZnT8A. The confidence 
bounds for unsuccessful sample collection for GADA, IA-2A and ZnT8A testing 
imply a 90% certainty that fewer than 4% would need retesting. Incorporating 
IAA potentially increases the rate of unsuccessful capillary sampling to 20%, 
largely because the more complex IAA radioimmunoassay requires five-fold 
greater volume than the other assays. Relatives were largely successful in 
collecting sufficient sample volumes to allow GADA, IA-2A and ZnT8A testing. 
Previously we demonstrated that this panel identified multiple autoantibody 
positive individuals with high sensitivity[5], the potential risk would therefore be 
missing individuals who are positive for IAA alone. A fail-safe capillary 
screening strategy would incorporate recall for venous sampling to confirm 
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positive results and for otherwise autoantibody negative individuals with 
insufficient sample for IAA testing. Requesting a higher minimum volume could 
more consistently provide sufficient volumes for all assays. Seroconversion for 
IAA tends to occur at an early age[13], which with current assays, may 
necessitate continued venous sampling to screen very young children.  
 
Strong preferences were demonstrated for home capillary sampling over 
venepuncture at a clinical centre particularly among families of children below 8 
years of age. Extending procedures for obtaining informed consent 
remotely by telephone or on-line could further facilitate testing. Our 
sampling kits appear user-friendly and clear written instructions were adequate 
for the majority of testers, with few referring to video instructions. No data were 
collected from families who declined capillary sampling or unreturned 
samples, potentially leading to bias. Importantly, these families were already 
familiar with capillary glucose testing; therefore feasibility of capillary 
sampling in the general population requires further study.  
 
Self-collected capillary blood samples are feasible and acceptable for 
autoantibody screening in individuals at risk of type 1 diabetes, showing 
advantages over dried blood collection and preferred over outpatient 
venepuncture, particularly in children. With additional benefits of improving 
convenience and efficiency, home autoantibody testing through capillary 
sampling could aid type 1 diabetes screening initiatives.  
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Table 1:  Demographics and rates of successful capillary blood sampling, 
overall and by age group (n=240). Successful capillary blood sampling was 
defined as obtaining samples of sufficient volume and quality (e.g. without 
excessive haemolysis) to allow definitive autoantibody results, including 
confirmation of positive results by repeat assay. 
 
 
 Overall 
Age (years) 
<=8  
(n=81) 
9-18 
(n=97) 
>18  
(n=62) 
Age 
Median (range) 
15.5 
(1-49) 
   
Gender n(%) 
Male 
Female 
Missing 
 
121 (51.5) 
114 (48.5) 
5 
 
39 (49.4) 
40 (50.6) 
2 
 
56 (57.7) 
41 (42.3) 
0 
 
26 (44.1) 
33 (55.9) 
3 
Overall successful sample 
rate n (%) 
201 (83.8) 68 (84.0) 80 (82.5) 53 (85.5) 
 GADA/ZnT8A/IA-2A 
successful sample rate 
 n (%)  
234 (97.5) 80 (98.8) 93 (95.9) 61 (98.4) 
IAA successful sample 
rate n (%) 
202 (84.2) 68 (84.0) 81 (83.5) 53 (85.5) 
 
 
